Casokefamide
Clinical data | |
---|---|
Other names | L-tyrosyl-D-alanyl-L-phenylalanyl-D-alanyl-L-tyrosinamide |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChemCID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C33H40N6O7 |
Molar mass | 632.718g·mol−1 |
3D model (JSmol) | |
| |
|
Casokefamide(INN), also known asβ-casomorphin 4027(β-CM-4027) and[D-Ala2,4,Tyr5]-β-casomorphin-5-amide,is aperipherally-specific,syntheticopioid pentapeptidewith theamino acid sequenceTyr-D-Ala-Phe-D-Ala-Tyr-NH2.[1]Derived from theβ-casomorphinsequence, it was designed with the intention of improving resistance todigestive enzymesso that it could be used as anantidiarrhealmedicine.[1][2]Unlike other casomorphins, which are generallyselectiveμ-opioid receptoragonists,casokefamide binds to both the μ- andδ-opioid receptors.[1]In aclinical study,casokefamide was found to be effective via the oral route for the treatment of chronicdiarrhea,and did not produce anyside effects.[2]However, further clinical development was not pursued and it was never marketed.
See also
[edit]References
[edit]- ^abcBrantl V, Picone D, Amodeo P, Temussi PA (March 1993). "Solution structure of casokefamide".Biochemical and Biophysical Research Communications.191(3): 853–9.doi:10.1006/bbrc.1993.1295.PMID8466524.
- ^abSchulte-Frohlinde E, Reindl W, Bierling D, et al. (March 2000). "Effects of oral casokefamide on plasma levels, tolerance, and intestinal transit in man".Peptides.21(3): 439–42.doi:10.1016/S0196-9781(00)00166-2.PMID10793229.S2CID44670226.